Genes and Blood Markers in Menière's Disease Compared With Vestibular Migraine
Studies blood and genetic factors in adults with Menière's disease or vestibular migraine.
Key facts
- Who runs it
- IRCCS San Raffaele
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes
- Status
- Recruiting
- People taking part
- 250 people, planned
- Started
- 9 Apr 2025
- Expected to end
- 12 Apr 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- a blood withdrawal will be obtained
- blood withdrawal
- Record updated
- 8 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with definite Menière's disease. It also includes people with vestibular migraine and people without vestibular problems for comparison.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Definite Menière's disease, as defined by the criteria of the Barany Society
- Earlier treatment
- People who had surgery before the examination, or had intratympanic therapy with steroids or gentamicin, cannot join
Main reasons for not taking part
- Surgery for the condition before the examination
- Intratympanic therapy with steroids before the examination
- Intratympanic therapy with gentamicin before the examination
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients with definite Menière's Disease according to the criteria of the Barany Society
Who cannot take part
- surgically treated before the examination or if they had undergone intratympanic therapy with steroids or gentamicin
Where in Italy
- IRCCS San RaffaeleMilan, ItalyContact: Roberto Carlo Teggi, MDTaking people
About the trial
What the trial wants to find out
Aim of this work was to assess the role of polymorphisms belonging to genes involved in the regulation of ionic homeostasis in Caucasian patients with Ménière Disease (MD) and compare results with a cohort of patients affected by vestibular migraine and a cohort of non vestibular subjects
The 3 groups in the trial
- Menière's Disease; vestibular migraine
Enrolled subjects should fulfil criteria for definite Menière's Disease (group MD) or definite Vestibular Migraine (VM) according to the ongoing criteria of the Barany Society. Moreover a cohort of non vertiginous subjects will be enrolled. A signed informed consent will be obtained by all subjects. A withdrawal for blood sample will be obtained to study genetic and biohumoral factors in the 3 groups
Treatment: a blood withdrawal will be obtained and blood withdrawal
- Menière's Disease (MD)
To be included, subjects should fulfill definite diagnostic criteria for MD. A blood withdrawal will be obtained to assess genetic and biohumoral aspects
Treatment: a blood withdrawal will be obtained and blood withdrawal
- Vestibular Migraine (VM)
To be included, subjects should fulfill definite diagnostic criteria for VM. A blood withdrawal will be obtained to assess genetic and biohumoral aspects
Treatment: a blood withdrawal will be obtained and blood withdrawal
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Genetics and Biohumoral Factors in Menière's Disease
- Plain-language title
- Genes and Blood Markers in Menière's Disease Compared With Vestibular MigraineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 8 April 2026